

RESEARCH

Open Access



# Urinary metabolite of pesticide, 3,5,6-trichloropyridinol, is associated with all-cause but not with cancer mortality

Fulu Qiao<sup>1†</sup>, Teng Ma<sup>1†</sup>, Xia Wang<sup>2</sup>, Feng Zhang<sup>3</sup> and Long Wan<sup>4\*</sup>

## Abstract

3,5,6-trichloropyridinol (TCPY) is a metabolite of chlorpyrifos and chlorpyrifos-methyl, whose presence in the environment is of potential toxicity to human. So, it is need to monitor and regulate TCPY levels to protect human health. However, it is not known whether TCPY is associated with all-cause and cancer mortality and to which degree its levels contributed to hazard risk. The study enrolled 3951 participants from the National Health and Nutrition Examination Surveys (NHANES). Ultra-high performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry was used to measure urinary TCPY. Cox proportional hazards regression analysis was performed to explore the associations between TCPY and all-cause and cancer mortality. The study found that the average level of TCPY in the cohort was 1.79 µg/L and was higher in those who had passed away. Individuals in the highest quartile had a 1.56-fold independent increase in rate for all-cause mortality compared to those in the lowest quartile (hazard ratio [HR] 1.56, 95% confidence interval 1.09–2.24,  $p=0.002$ ). However, while the univariate model showed a hazard ratio of 2.37 (1.19–4.71) for the highest quartile in regards to cancer mortality, this association disappeared after adjusting for demographics, lifestyles, and comorbidities. Exposure to urinary 3,5,6-trichloropyridinol, as a result of insecticide exposure, increased the rate of all-cause mortality but was not independently associated with cancer mortality.

**Keywords** 3,5,6-trichloropyridinol, Cancer mortality, All-cause mortality, NHANES, Pesticides

## Introduction

Pesticides, such as pyrethroids, organophosphorus, and phenoxyalkanoic acid insecticides, are synthetic compounds commonly used to control insects in agriculture

and gardening [5]. 3,5,6-trichloropyridinol (TCPY) is a metabolite of the organophosphate insecticides, chlorpyrifos and chlorpyrifos-methyl formed in the environment, during metabolism in living organisms, or during chemical degradation [12]. Chlorpyrifos and its metabolites have been associated with adverse effects on non-target organisms, including nervous system [17], reproductive system [1], and overall health [13]. Understanding the toxicology of TCPY is crucial for assessing its potential health risks to humans.

While pesticides are essential for crop yield, they have also been linked to adverse health effects, especially in those exposed to them in agricultural settings [8]. Accordingly, measuring urinary organophosphate insecticide metabolites is crucial in estimating human exposure and assessing the potential for health consequences.

<sup>†</sup>Fulu Qiao and Teng Ma have contributed equally to this work.

\*Correspondence:

Long Wan

lwgxst@qq.com

<sup>1</sup> Department of Breast Surgery, Taian City Central Hospital, Tai'an 271000, China

<sup>2</sup> Department of Geriatric Cardiology, Taian City Central Hospital, Tai'an 271000, China

<sup>3</sup> Department of Surgical Oncology, Taian City Central Hospital, Tai'an 271000, China

<sup>4</sup> Department of Radiotherapy, Taian City Central Hospital, 29 Longtan Road, Tai'an 271000, China

Past research has shown a correlation between urinary TCPY and decreased serum testosterone in males [11] as well as a decrease in estradiol and sex hormone-binding globulin in females [9].

The primary pyrethroid metabolite, 3-phenoxybenzoic acid, has been found to increase the risk of mortality [2]. Besides, agricultural chlorpyrifos exposure was associated with mortality [7]. However, the relationship between urinary TCPY and mortality remains unclear.

## Methods

### Study population

The study's population consisted of 3951 participants with complete records of urinary TCPY and mortality status, sourced from the National Health and Nutrition Examination Survey during the years 2007–2010, which is a survey of studies designed to assess the health and nutritional status of adults and children in the United States. Approval for the study was granted by the National Center for Health Statistics under Protocol #2005–06.

### Exposure and covariates

Urine specimens are processed, stored, and shipped to the Centers for Disease Control and Prevention for analysis. Urinary 3,5,6-trichloropyridinol was extracted and concentrated from the urine matrix using an automated solid phase extraction system. Selective separation of the analytes is achieved using high-performance liquid chromatography with a gradient elution program. Sensitive detection of the analytes is performed by a triple quadrupole mass spectrometer with a heated electrospray ionization source. Isotopically labeled internal standards are used for precise and accurate quantification (<https://www.cdc.gov/nchs/data/nhanes/2013-2014/labmethods/UPHOPM-H-MET-508.pdf>). The half-life of TCPY in urine samples was short and metabolized rapidly, but it can vary depending on several factors, including individual metabolism, exposure levels, and other physiological factors. Those TCPY values below the limit of detection (LOD) were expressed as LOD/sqrt 2 and 84 participants had TCPY below the LOD.

From the survey questionnaires, sociodemographic variables, lifestyle variables, and comorbidities were collected. Briefly, physical activity, hypertension, diabetes and CVD were self-reported. Poverty-income ratio was the ratio of the number of people (in a given age group) whose income falls below the poverty line and a ratio less than 1 meant that the income was less than the poverty level.

Mortality status was determined through linkage with the National Death Index by 31 December 2015. We classified causes of deaths according to the codes of ICD-10

(international statistical classification of diseases, 10th revision). All-cause mortality included death from all diseases, while cancer mortality is death specifically from cancer (codes C00-C97). Only the underlying cause of death was used for cancer analysis.

### Statistical analysis

Statistical analyses consisted of comparisons between the TCPY quartiles using chi-square and student t-tests for categorical and continuous variables, respectively. Multivariable Cox proportional hazards regression models were used to estimate the association between TCPY and mortality rate, while restricted cubic spline models were used to explore nonlinearity. R 3.6.2 was used to perform all statistical analyses, with statistical significance determined at a p-value < 0.05.

## Results

After excluding participants with missing records on TCPY (n=190) and mortality (n=84), a total of 3,951 participants (age: 18–80 years) were included in our study, with a mean TCPY level of 1.79 µg/L. Table 1 shows the main characteristics of the participants. Deceased individuals were older ( $68.2 \pm 13.7$  in non-survivors group vs.  $46.7 \pm 17.8$  in survivors group), more male (57.6% vs. 47.1%), and non-Hispanic white (57.9% vs. 45.7%) (all  $p < 0.001$ ). The level of urinary TCPY was higher in non-survivors group ( $2.09 \pm 2.15$  vs.  $1.76 \pm 1.92$  µg/L;  $p = 0.003$ ).

There were 342 death from all causes and 80 death from cancer. Compared to the lowest quartile, the highest quartile of TCPY was associated with increased all-cause mortality in unadjusted Model 1 (hazard ratio [HR] 2.67, 95% confidence interval [CI] 1.88 to 3.79;  $p < 0.001$ ), partly-adjusted Model 2 (HR 1.46, 95% CI 1.02 to 2.08;  $p = 0.038$ ), and fully-adjusted Model 3 (HR 1.56, 95% CI 1.09 to 2.24;  $p = 0.015$ ) (Table 2). The 2nd and 3th quartile also showed a positive relationship with all-cause mortality in Model 1 (for the 2nd quartile, HR 1.44, 95% CI 1.04 to 1.98,  $p = 0.027$ ; or the 3th quartile, HR 1.61, 95% CI 1.14 to 2.28,  $p = 0.007$ ), but it disappeared in adjusted models.

However, in terms of cancer mortality (Table 3), while the highest quartile of TCPY was associated with a 2.37-fold rate (95% CI 1.19, 4.71;  $p = 0.014$ ), this association disappeared after adjusting for urinary creatinine, age, gender, race, education, poverty-income ratio, BMI, drinker, smoker, activity, hypertension, diabetes, and CVD (HR 1.57, 95% CI 0.77 to 3.20;  $p = 0.219$ ). These results suggested that urinary TCPY was not independently associated with cancer mortality.

**Table 1** Characteristics of the study population

| Variable                  | Overall (n = 3951) | Survivors (n = 3609) | Non-survivors (n = 342) | P value |
|---------------------------|--------------------|----------------------|-------------------------|---------|
| Age, years                | 48.6 (18.5)        | 46.7 (17.8)          | 68.2 (13.7)             | < 0.001 |
| Male, %                   | 1898 (48.0)        | 1701 (47.1)          | 197 (57.6)              | < 0.001 |
| Race, %                   |                    |                      |                         | < 0.001 |
| Non-Hispanic white        | 1847 (46.7)        | 1649 (45.7)          | 198 (57.9)              |         |
| Non-Hispanic black        | 761 (19.3)         | 692 (19.2)           | 69 (20.2)               |         |
| Mexican American          | 724 (18.3)         | 687 (19.0)           | 37 (10.8)               |         |
| Others                    | 619 (15.7)         | 581 (16.1)           | 38 (11.1)               |         |
| Education, %              |                    |                      |                         | < 0.001 |
| Less than high school     | 1176 (29.8)        | 1043 (28.9)          | 133 (38.9)              |         |
| High school or equivalent | 896 (22.7)         | 812 (22.5)           | 84 (24.6)               |         |
| College or above          | 1879 (47.6)        | 1754 (48.6)          | 125 (36.5)              |         |
| Poverty-income ratio, %   |                    |                      |                         | < 0.001 |
| < 1                       | 901 (22.8)         | 815 (22.6)           | 86 (25.1)               |         |
| 1 ~ 3                     | 1671 (42.3)        | 1486 (41.2)          | 185 (54.1)              |         |
| > 3                       | 1379 (34.9)        | 1308 (36.2)          | 71 (20.8)               |         |
| BMI, kg/m <sup>2</sup>    | 28.9 (6.8)         | 28.9 (6.8)           | 28.9 (6.9)              | 0.876   |
| Drinker (%)               | 2268 (57.4)        | 2086 (57.8)          | 182 (53.2)              | 0.114   |
| Smoker, %                 |                    |                      |                         | < 0.001 |
| Never                     | 2782 (70.4)        | 2564 (71.0)          | 218 (63.7)              |         |
| Past                      | 192 (4.9)          | 183 (5.1)            | 9 (2.6)                 |         |
| Current                   | 977 (24.7)         | 862 (23.9)           | 115 (33.6)              |         |
| Activity, %               |                    |                      |                         | 0.002   |
| Inactive                  | 1076 (27.2)        | 966 (26.8)           | 110 (32.2)              |         |
| Moderate                  | 1669 (42.2)        | 1514 (42.0)          | 155 (45.3)              |         |
| Vigorous                  | 1206 (30.5)        | 1129 (31.3)          | 77 (22.5)               |         |
| Hypertension, %           | 722 (18.3)         | 600 (16.6)           | 122 (35.7)              | < 0.001 |
| Diabetes, %               | 609 (15.4)         | 479 (13.3)           | 130 (38.0)              | < 0.001 |
| CVD, %                    | 399 (10.1)         | 283 (7.8)            | 116 (33.9)              | < 0.001 |
| Creatinine, mg/dL         | 125.2 (80.1)       | 126.8 (81.2)         | 107.9 (64.1)            | < 0.001 |
| TCPY, µg/L                | 1.79 (1.93)        | 1.76 (1.91)          | 2.09 (2.15)             | 0.003   |

Data are presented as mean (SD), or n (%). BMI body mass index, CVD cardiovascular diseases, TCPY, 3,5,6-trichloropyridinol

**Table 2** The association between TCPY and all-cause mortality

|               | Event | Model 1           |         | Model 2           |       | Model 3           |       |
|---------------|-------|-------------------|---------|-------------------|-------|-------------------|-------|
|               |       | HR                | P       | HR                | P     | HR                | P     |
| TCPY, µg/L    |       |                   |         |                   |       |                   |       |
| < 0.535       | 70    | Ref.              | –       | Ref.              | –     | Ref.              | –     |
| 0.535 ~ 1.220 | 86    | 1.44 [1.04, 1.98] | 0.027   | 1.11 [0.80, 1.53] | 0.538 | 1.12 [0.81, 1.54] | 0.495 |
| 1.220 ~ 2.330 | 78    | 1.61 [1.14, 2.28] | 0.007   | 1.11 [0.79, 1.57] | 0.538 | 1.09 [0.77, 1.53] | 0.623 |
| > 2.330       | 108   | 2.67 [1.88, 3.79] | < 0.001 | 1.46 [1.02, 2.08] | 0.038 | 1.56 [1.09, 2.24] | 0.015 |
| Continuous    | 342   | 1.14 [1.09, 1.20] | < 0.001 | 1.04 [0.98, 1.10] | 0.197 | 1.05 [0.99, 1.11] | 0.112 |

Model 1: adjusted for urinary creatinine

Model 2: adjusted for urinary creatinine, age, gender, race, education, poverty-income ratio, BMI, drinker, smoker and activity

Model 3: adjusted for urinary creatinine, age, gender, race, education, poverty-income ratio, BMI, drinker, smoker, activity, hypertension, diabetes, and CVD

**Table 3** The association between TCPY and cancer mortality

|             | Event | Model 1           |       | Model 2           |       | Model 3           |       |
|-------------|-------|-------------------|-------|-------------------|-------|-------------------|-------|
|             |       | HR                | P     | HR                | P     | HR                | P     |
| TCPY, µg/L  |       |                   |       |                   |       |                   |       |
| <0.535      | 19    | Ref.              | –     | Ref.              | –     | Ref.              | –     |
| 0.535~1.220 | 17    | 1.03 [0.53, 2.00] | 0.940 | 0.87 [0.45, 1.71] | 0.690 | 0.90 [0.46, 1.76] | 0.752 |
| 1.220~2.330 | 16    | 1.16 [0.57, 2.35] | 0.689 | 0.93 [0.46, 1.89] | 0.838 | 0.90 [0.44, 1.83] | 0.772 |
| >2.330      | 28    | 2.37 [1.19, 4.71] | 0.014 | 1.55 [0.76, 3.17] | 0.225 | 1.57 [0.77, 3.20] | 0.219 |
| Continuous  | 80    | 1.14 [1.03, 1.27] | 0.001 | 1.06 [0.94, 1.19] | 0.351 | 1.05 [0.94, 1.18] | 0.399 |

Model 1: adjusted for urinary creatinine

Model 2: adjusted for urinary creatinine, age, gender, race, education, poverty-income ratio, BMI, drinker, smoker and activity

Model 3: adjusted for urinary creatinine, age, gender, race, education, poverty-income ratio, BMI, drinker, smoker, activity, hypertension, diabetes, and CVD


Furthermore, restricted cubic splines didn't show a nonlinear relationship between urinary TCPY and all-cause mortality with  $p$  for nonlinearity = 0.07 (Fig. 1).

Age can bias the estimated effects of risk factors in epidemiologic cohort studies of chronic diseases. Therefore, we have added a sensitivity analysis with age as the time scale and left truncation at enrollment (Table 4). Smoking was an important confounder; therefore, we re-analyzed the data by ruling out the smokers (Table 5). The conclusion was not changed.

**Discussion**

Our study found that urinary 3,5,6-trichloropyridinol was associated with all-cause mortality, although it was not independently associated with cancer mortality. Therefore, our findings suggested a potential risk of exposure to TCPY for mortality.

Due to widespread exposure to pesticides, their potential adverse health effects should not be ignored. A study found that pyrethroid pesticides increased the risk of all-cause and cardiovascular mortality [2]. Several epidemiological studies reported the association between pesticide exposure and endocrine system alterations. For example, urinary non-persistent pesticide was negatively



**Fig. 1** The dose–response analysis between urinary TCPY and all-cause mortality **A** or cancer mortality **B**

**Table 4** A sensitive analysis of association between TCPY and all-cause mortality with age as the time scale

|               | Model 1          |       | Model 2          |         | Model 3          |         |
|---------------|------------------|-------|------------------|---------|------------------|---------|
|               | HR               | P     | HR               | P       | HR               | P       |
| TCPY, µg/L    |                  |       |                  |         |                  |         |
| < 0.535       | Ref.             | –     | Ref.             | –       | Ref.             | –       |
| 0.535 ~ 1.220 | 1.32 [0.92–1.84] | 0.139 | 0.91 [0.48–1.76] | 0.792   | 0.95 [0.47–1.80] | 0.816   |
| 1.220 ~ 2.330 | 1.15 [1.05–2.06] | 0.012 | 1.85 [1.31–2.57] | < 0.001 | 1.91 [0.99–4.07] | 0.056   |
| > 2.330       | 2.15 [1.05–4.35] | 0.038 | 2.18 [1.08–4.08] | 0.031   | 1.88 [1.31–2.58] | < 0.001 |

Model 1: adjusted for urinary creatinine

Model 2: adjusted for urinary creatinine, gender, race, education, poverty-income ratio, BMI, drinker, smoker and activity

Model 3: adjusted for urinary creatinine, age, gender, race, education, poverty-income ratio, BMI, drinker, smoker, activity, hypertension, diabetes, and CVD


**Table 5** A sensitive analysis of association between TCPY and all-cause mortality in population who never smoked

|               | Event | Model 1           |         | Model 2           |       | Model 3           |       |
|---------------|-------|-------------------|---------|-------------------|-------|-------------------|-------|
|               |       | HR                | P       | HR                | P     | HR                | P     |
| TCPY, µg/L    |       |                   |         |                   |       |                   |       |
| < 0.535       | 42    | Ref.              | –       | Ref.              | –     | Ref.              | –     |
| 0.535 ~ 1.220 | 54    | 1.47 [0.97, 2.22] | 0.066   | 1.18 [0.78, 1.78] | 0.428 | 1.20 [0.80, 1.81] | 0.382 |
| 1.220 ~ 2.330 | 48    | 1.63 [1.05, 2.54] | 0.031   | 1.08 [0.70, 1.67] | 0.725 | 1.07 [0.69, 1.66] | 0.752 |
| > 2.330       | 74    | 3.12 [2.01, 4.84] | < 0.001 | 1.59 [1.02, 2.48] | 0.039 | 1.64 [1.06, 2.55] | 0.027 |
| Continuous    | 218   | 1.19 [1.12, 1.26] | < 0.001 | 1.07 [1.00, 1.15] | 0.042 | 1.07 [1.00, 1.15] | 0.038 |

associated with serum sex hormones [9]. Pyrethroid exposure was related to the alteration of reproductive hormone levels in males [14].

TCPY, the metabolite of chlorpyrifos and chlorpyrifos-methyl, was negatively associated with testosterone and estradiol in female adolescents [9] and adult males [10, 11]. In addition to sex hormones, TCPY has been reported to increase the risk of blood pressure

dysregulation [4] thyroid dysfunction [6] and cognitive and behavior deficits [3]. Furthermore, we observed that higher TCPY levels were associated with an increased rate of all-cause mortality, although we did not find an independent association of cancer mortality. Dose-response analysis and adjustments for additional variables revealed that TCPY had a positive association with all-cause mortality.



**Fig. 2** An illustration graph explaining the physiopathological mechanism between TCPY and mortality. TCPY decreased the levels of testosterone and estradiol, causing endocrine dysfunction. TCPY promoted the expression of IL-1α and Bax /Bcl-2, and caspase 9/3, which upregulated inflammatory responses and cell apoptosis. These results contributed to mortality collectively. *IL-1α* Interleukin-1α, *Bcl2* B-cell lymphoma-2, *Bax* Bcl-2-associated X protein

There may be various underlying mechanisms driving the positive correlation between TCPY and all-cause mortality (Fig. 2). Firstly, urinary TCPY was inversely related to serum testosterone in males [11] and estradiol in females [9]. Besides, TCPY exposure resulted in a strong induction of IL1 $\alpha$ , and inflammatory response, being cytotoxic to human embryonic kidney cells [15]. Finally, TCPY up-regulated the expression level of Bax / Bcl-2, and caspase-9/-3 activation, inducing the apoptosis of human hepatocytes [16]. However, more research is necessary to elucidate the biological mechanisms underlying this association.

Several limitations need to be considered when interpreting our findings. Firstly, a one-time point measure may not reflect the long-term burden of TCPY. Secondly, numerous potential variables were not included in our models, such as liver function, and kidney function etc. Third, our findings based on a relatively small sample size and short-term follow-up require cautious interpretation. Finally, more biological evidences should be investigated to explain our findings.

## Conclusion

In conclusion, we found that urinary 3,5,6-trichloropyridinol was independently associated with all-cause mortality and was not independently associated with cancer mortality.

## Acknowledgements

Not applicable.

## Author contributions

Z F and W L designed the study. Q F and M T performed the statistical analysis. W X wrote the manuscript. All authors read and approved the final manuscript.

## Funding

Not applicable.

## Availability of data and materials

All the data could be available upon request from the corresponding author.

## Declarations

### Ethics approval and consent to participate

The study was approved by the institutional review board of National Center for Health Statistics (Protocol #2005-06) and written informed consent was obtained from all subjects.

### Consent for publication

Not applicable.

### Competing interests

The authors declare that they have no competing interests.

## References

- Alaa-Eldin EA, El-Shafei DA, Abouhashem NS (2017) Individual and combined effect of chlorpyrifos and cypermethrin on reproductive system of adult male albino rats. *Environ Sci Pollut Res Int* 24:1532–1543
- Bao W, Liu B, Simonsen DW, Lehmler HJ (2020) Association between exposure to pyrethroid insecticides and risk of all-cause and cause-specific mortality in the general US adult population. *JAMA Intern Med* 180:367–374
- Fortenberry GZ, Meeker JD, Sanchez BN, Barr DB, Panuwet P, Bellinger D, Schnaas L, Solano-Gonzalez M, Ettinger AS, Hernandez-Avila M, Hu H, Tellez-Rojo MM (2014) Urinary 3,5,6-trichloro-2-pyridinol (TCPY) in pregnant women from Mexico City: distribution, temporal variability, and relationship with child attention and hyperactivity. *Int J Hyg Environ Health* 217:405–412
- Glover F, Eisenberg ML, Belladelli F, Del Giudice F, Chen T, Mulloy E, Caudle WM (2022) The association between organophosphate insecticides and blood pressure dysregulation: NHANES 2013–2014. *Environ Health* 21:74
- Hertz-Picciotto I, Sass JB, Engel S, Bennett DH, Bradman A, Eskenazi B, Lanphear B, Whyatt R (2018) Organophosphate exposures during pregnancy and child neurodevelopment: Recommendations for essential policy reforms. *PLoS Med* 15:e1002671
- Jain RB (2017) Association between thyroid function and urinary levels of 3,5,6-trichloro-2-pyridinol: data from NHANES 2007–2008. *Environ Sci Pollut Res Int* 24:2820–2826
- Lee WJ, Alavanja MC, Hoppin JA, Rusiecki JA, Kamel F, Blair A, Sandler DP (2007) Mortality among pesticide applicators exposed to chlorpyrifos in the agricultural health study. *Environ Health Perspect* 115:528–534
- Leibholz J (1986) The utilization of lysine by young pigs from nine protein concentrates compared with free lysine in young pigs fed ad lib. *Br J Nutr* 55:179–186
- Liang H, Wu X, Yao H, Weng X, Liu S, Chen J, Li Y, Wu Y, Wen L, Chen Q, Jing C (2022) Association of urinary metabolites of non-persistent pesticides with serum sex hormones among the US females: NHANES 2013–2014. *Chemosphere* 300:134577
- Meeker JD, Ryan L, Barr DB, Hauser R (2006) Exposure to nonpersistent insecticides and male reproductive hormones. *Epidemiology* 17:61–68
- Meeker JD, Ravi SR, Barr DB, Hauser R (2008) Circulating estradiol in men is inversely related to urinary metabolites of nonpersistent insecticides. *Reprod Toxicol* 25:184–191
- Morgan MK, Sheldon LS, Croghan CW, Jones PA, Robertson GL, Chuang JC, Wilson NK, Lyu CW (2005) Exposures of preschool children to chlorpyrifos and its degradation product 3,5,6-trichloro-2-pyridinol in their everyday environments. *J Expo Anal Environ Epidemiol* 15:297–309
- Nandi NK, Vyas A, Akhtar MJ, Kumar B (2022) The growing concern of chlorpyrifos exposures on human and environmental health. *Pestic Biochem Physiol* 185:105138
- Radwan M, Jurewicz J, Wielgomas B, Sobala W, Piskunowicz M, Radwan P, Hanke W (2014) Semen quality and the level of reproductive hormones after environmental exposure to pyrethroids. *J Occup Environ Med* 56:1113–1119
- Van Emon JM, Pan P, van Breukelen F (2018) Effects of chlorpyrifos and trichloropyridinol on HEK 293 human embryonic kidney cells. *Chemosphere* 191:537–547
- Zhang N, Zhu L, Zhang R, Zhang C, Cheng J, Tao L, Zhang Y, Xu W (2021) Evaluation of toxicological effects of organophosphorus pesticide metabolites on human HepG2 cells. *Environ Toxicol Pharmacol* 88:103741
- Zhang W, Fan R, Luo S, Ying L, Jin Y, Li Y, Xiong M, Yuan X, Jia L, Chen Y (2022) Antagonistic effects and mechanisms of carbendazim and chlorpyrifos on the neurobehavior of larval zebrafish. *Chemosphere* 293:133522

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.